Glenmark Pharmaceuticals has informed that it attached media release today titled ‘Glenmark becomes the First Pharmaceutical Company to launch Teneligliptin + Pioglitazone Fixed-Dose Combination Drug for Type 2 Diabetes in India’.
The above information is a part of company’s filings submitted to BSE.